Several other research analysts also recently issued reports on the company. Roth Capital set a $14.00 price objective on Syros Pharmaceuticals and gave the stock a buy rating in a report on Sunday, December 2nd. Oppenheimer set a $26.00 price objective on Syros Pharmaceuticals and gave the stock a buy rating in a report on Tuesday, November 13th. Zacks Investment Research downgraded Syros Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, November 6th. BidaskClub raised Syros Pharmaceuticals from a strong sell rating to a sell rating in a report on Tuesday, November 6th. Finally, JMP Securities set a $33.00 target price on shares of Syros Pharmaceuticals and gave the company a buy rating in a research report on Thursday, November 1st. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The company presently has an average rating of Hold and an average target price of $19.29.
NASDAQ:SYRS opened at $7.50 on Monday. Syros Pharmaceuticals has a 52-week low of $6.25 and a 52-week high of $13.86. The firm has a market cap of $235.58 million, a price-to-earnings ratio of -3.52 and a beta of 0.80.
Institutional investors have recently modified their holdings of the business. Cubist Systematic Strategies LLC bought a new stake in shares of Syros Pharmaceuticals during the 2nd quarter valued at $119,000. MetLife Investment Advisors LLC bought a new stake in shares of Syros Pharmaceuticals during the 2nd quarter valued at $134,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Syros Pharmaceuticals during the 2nd quarter valued at $177,000. Citadel Advisors LLC bought a new stake in shares of Syros Pharmaceuticals during the 2nd quarter valued at $186,000. Finally, Rhumbline Advisers raised its position in shares of Syros Pharmaceuticals by 87.6% during the 2nd quarter. Rhumbline Advisers now owns 22,472 shares of the company’s stock valued at $229,000 after acquiring an additional 10,494 shares during the last quarter. Institutional investors own 61.26% of the company’s stock.
Syros Pharmaceuticals Company Profile
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; and SY-1365, a selective CDK7 inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian cancer, breast cancer, and AML.
Featured Article: Cost of Debt
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.